For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Tafamidis and Tafamidis meglumine represents a true advancement . These groundbreaking therapies protect the transthyretin protein, halting its damaging build-up and alleviati